Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ernexa Therapeutics (ERNA) Shares Outstanding (2016 - 2025)

Historic Shares Outstanding for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to $7.8 million.

  • Ernexa Therapeutics' Shares Outstanding rose 207423.82% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year increase of 207423.82%. This contributed to the annual value of $3.4 million for FY2024, which is 84903.05% up from last year.
  • Latest data reveals that Ernexa Therapeutics reported Shares Outstanding of $7.8 million as of Q3 2025, which was up 207423.82% from $7.5 million recorded in Q2 2025.
  • Ernexa Therapeutics' Shares Outstanding's 5-year high stood at $41.5 million during Q1 2021, with a 5-year trough of $361000.0 in Q4 2023.
  • Over the past 5 years, Ernexa Therapeutics' median Shares Outstanding value was $3.2 million (recorded in 2022), while the average stood at $5.7 million.
  • In the last 5 years, Ernexa Therapeutics' Shares Outstanding crashed by 9332.72% in 2024 and then soared by 207423.82% in 2025.
  • Quarter analysis of 5 years shows Ernexa Therapeutics' Shares Outstanding stood at $2.6 million in 2021, then surged by 97.04% to $5.1 million in 2022, then plummeted by 92.96% to $361000.0 in 2023, then surged by 849.03% to $3.4 million in 2024, then skyrocketed by 129.1% to $7.8 million in 2025.
  • Its last three reported values are $7.8 million in Q3 2025, $7.5 million for Q2 2025, and $3.5 million during Q1 2025.